In ordering a new $877 million anthrax vaccine last month, the federal government said it was a major step toward creating a “bioshield” to protect Americans from germ warfare. But delivering that protection may be difficult: the vaccine is unproven in humans, the maker has legal and accounting troubles, and health officials are not prepared to distribute the vaccine quickly if it is needed.
